newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026

  • Ascentage Pharma Group International announced six abstracts from its clinical studies are now available on the ASCO official website for the 2026 American Society of Clinical Oncology Annual Meeting.
  • Three abstracts are selected for rapid oral presentations and three for poster presentations.
  • The studies report data on three lead drug candidates: BCR-ABL inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), and MDM2-p53 inhibitor alrizomadlin (APG-115).
  • The 2026 ASCO Annual Meeting will be held in person in Chicago, IL, and online from May 29 to June 2, 2026.
  • Rapid oral presentation 6513 highlights Phase Ib data showing four of five patients with MRD positivity achieved complete response when olverembatinib was combined with blinatumomab for CML-LBP or Ph+ BCP-ALL.
  • Rapid oral presentation 6510 reports updated data for olverembatinib as second-line therapy in CP-CML, showing a 91.3% complete cytogenetic response rate and 60.9% major molecular response rate at cycle 24.
  • Rapid oral presentation 10012 details pediatric trials of alrizomadlin alone or with lisaftoclax for relapsed/metastatic rhabdomyosarcoma, noting an objective response rate of 30% in the combination group with a manageable safety profile.
  • Poster presentation 11539 reveals olverembatinib efficacy in SDH-deficient GIST with a 25.7-month median progression-free survival and identifies a mechanism involving the p38-CD36 pathway.
  • Poster presentation TPS6608 outlines the ongoing global Phase III POLARIS-2 trial of olverembatinib for chronic-phase CML, evaluating patients with prior TKI failure or T315I mutations.
  • Poster presentation TPS7101 describes the ongoing global Phase III GLORA trial of lisaftoclax combined with a BTK inhibitor for previously treated CLL/SLL patients with suboptimal response to BTKi monotherapy.
  • Olverembatinib is approved in China for CML with T315I mutations or TKI resistance, while lisaftoclax is approved in China for CLL/SLL after prior systemic therapy.
  • Ascentage Pharma is conducting multiple registrational Phase III trials for its drug candidates in the US, Europe, China, and globally.